Treatment of Hepatitis C Virus Infection in Kidney Transplant Recipients: Case Report

Chronic hepatitis C virus (HCV) infection exists in a large proportion of patients undergoing renal transplantation. Nowadays it is not considered to be an absolute contraindication to transplantation; however, it is associated with an increased risk for the patient and accounts for a shorter half-life of the renal allograft. We present three transplant recipients who displayed serious hepatic dysfunction after renal transplantation due to an HCV infection. In two of these cases, the liver biopsies established the diagnosis of FCH. In the third case, the liver biopsy was compatible with the early stages of FCH. All patients were started on peg-interferon alfa 2-b and ribavirin with subsequent normalization of hepatic function and early complete viral responses.

Burkitt’s Lymphoma Related to Epstein–Barr Virus Infection During Pregnancy

Setting: Burkitt’s lymphoma is a rare form of cancer and is an extremely rare diagnosis during pregnancy. This form of lymphoma is a very fast growing B cell neoplasm and chemotherapy is the treatment of choice for the disease in all its stages. Case report: The authors describe the case of a Caucasian 40-year-old nulliparous woman, with previous known Epstein–Barr virus infection, that presents at 28 weeks gestation with supraclavicular adenopathy and multiple bilateral breast nodules, in which biopsy showed non-Hodgkin lymphoma, Burkitt’s type. Discussion: There are few described cases of Burkitt’s lymphoma during pregnancy and in general the outcomes have been poor. In most of the cases, the patients were not treated by current standards or instead had a late diagnosis. This neoplasia is the most rapidly progressive human tumor, and any delay in initiating therapy can adversely aVect patient’s prognosis. The authors discuss treatment options in pregnancy and its perinatal implications.

Morbilidade Cardiovascular em Crianças com Infecção pelo Vírus da Imunodeficiência Humana

Na infecção pelo vírus da imunodeficiência humana (VIH) estão descritas alterações cardiovasculares, tanto estruturais como funcionais. Com o objectivo de fazer o rastreio das referidas alterações no propósito de uma intervenção terapêutica precoce, foi efectuada uma avaliação clínica e laboratorial prospectiva em 32 crianças com infecção pelo VIH, com idades compreendidas entre três meses e 13 anos (média = 3.11 +/- 3.51 anos). Em 90% dos doentes identificou-se transmissão perinatal. Vinte e duas crianças (69%) estavam sintomáticas, sendo a sintomatologia moderada em nove e grave em oito. Catorze doentes tinham alterações imunológicas e oito delas apresentavam imunosupressão grave. Vinte e oito crianças (88%)tinham infecção pelo VIH 1 e seis tinham infecção recente pelo Vírus de Ebstein-Barr. Dezanove doentes receberam tratamento com zidovudina e 14 com imunoglobulinas por via endovenosa. Foram detectadas 19 alterações cardiovasculares em 15 doentes (47%), nomeadamente: 11 casos de hipertensão pulmonar por critérios ecocardiográficos, (oito delas tinham infiltrados intersticiais na radiografia do tórax) e quatro casos de disfunção ventricular esquerda que, por isso, iniciaram terapêutica anticongestiva. As restantes anomalias estruturais ou funcionais foram: persistência de canal arterial; hipertrofia do septo interventricular; prolapso da válvula mitral e derrame pericárdico cada uma delas em um caso. No electrocardiograma de superfície quatro crianças apresentaram critérios de hipertrofia ventricular direita, uma tinha hipertrofia ventricular esquerda e duas tinham alterações inespecíficas de repolarização ventricular. Em 14 doentes (44%) verificou-se no ECG de 24 horas taquicardia sinusal com uma frequência cardíaca média superior ao percentil 95. As anomalias cardiovasculares foram mais frequentes nas crianças com estadios mais avançados de doença. Conclusões: As anomalias cardiovasculares são frequentes em crianças com infecção pelo VIH em estadios avançados; a hipertensão pulmonar é a anomalia cardiovascular mais frequentemente detectada e está associada a patologia respiratória crónica ou recorrente; o acompanhamento cardiológico está indicado nas crianças com infecção pelo vírus da imunodeficiência humana.

Retinite Sifilítica em Doente Seropositivo para VIH

Os autores apresentam o caso clínico de um homem de 25 anos de idade, internado por diminuição progressiva da acuidade visual. Tinha-lhe sido diagnosticada sífilis primária 5 anos antes e apresentava seropositividade para VIH1 desde há 2 anos. A terapêutica com penicilina levou à melhoria das lesões de retinite, com recuperação da acuidade visual, pelo que foi feito o diagnóstico de retinite sifilítica.

Infecção pelo Vírus da Imunodeficiência Humana. Experiência de um Serviço de Medicina Interna

Apresenta-se a experiência recentemente adquirida na assistência a doentes infectados pelo vírus da imunodeficiência humana (VIH) num serviço de Medicina Interna de um hospital central. Descreve-se uma população de 107 doentes com 157 internamentos, num período de 7 anos (1987-1994), nas suas características epidemiológicas e clínicas, bem como alguns aspectos de diagnóstico nas infecções oportunistas e terapêutica antiviral. Procura-se acompanhar as várias etapas constituintes de um circuito que todos os doentes percorrem desde a sua admissão hospitalar até à alta e retorno à comunidade. Salientam-se as carências em cada uma destas fases, apontando-se algumas sugestões visando melhorar esta assistência, embora o caminho a percorrer nos pareça ainda bastante longo.

Infecção pelo Vírus da Hepatite B em Doentes Sujeitos a Terapêutica Imunossupressora ou Quimioterapia Citotóxica. A Propósito de um Caso Clínico

A reactivação do vírus da hepatite B em doentes com neoplasias hematológicas é uma complicação frequente da quimioterapia ou da terapêutica imunomoduladora. Os autores descrevem o caso dum doente com linfoma não-Hodgkin e história de infecção passada pelo VHB que desenvolveu hepatite fulminante após quimioterapia. Os mecanismos de reactivação do VHB são discutidos e as recomendações sobre profilaxia são apresentadas.

Environment and Health in Children Day Care Centres (ENVIRH) - Study Rationale and Protocol

Background: Indoor air quality (IAQ) is considered an important determinant of human health. The association between exposure to volatile organic compounds, particulate matter, house dust mite, molds and bacteria in day care centers (DCC) is not completely clear. The aim of this project was to study these effects. Methods --- study design: This study comprised two phases. Phase I included an evaluation of 45 DCCs (25 from Lisbon and 20 from Oporto, targeting 5161 children). In this phase, building characteristics, indoor CO2 and air temperature/relative humidity, were assessed. A children’s respiratory health questionnaire derived from the ISAAC (International Study on Asthma and Allergies in Children) was also distributed. Phase II encompassed two evaluations and included 20 DCCs selected from phase I after a cluster analysis (11 from Lisbon and 9 from Oporto, targeting 2287 children). In this phase, data on ventilation, IAQ, thermal comfort parameters, respiratory and allergic health, airway inflammation biomarkers, respiratory virus infection patterns and parental and child stress were collected. Results: In Phase I, building characteristics, occupant behavior and ventilation surrogates were collected from all DCCs. The response rate of the questionnaire was 61.7% (3186 children). Phase II included 1221 children. Association results between DCC characteristics, IAQ and health outcomes will be provided in order to support recommendations on IAQ and children’s health. A building ventilation model will also be developed. Discussion: This paper outlines methods that might be implemented by other investigators conducting studies on the association between respiratory health and indoor air quality at DCC.

Influenza A(H1N1)pdm09 Resistance and Cross-Decreased Susceptibility to Oseltamivir and Zanamivir Antiviral Drugs

Neuraminidase inhibitors (NAIs) oseltamivir and zanamivir are currently the only effective antiviral drugs available worldwide for the management of influenza. The potential development of resistance is continually threatening their use, rationalizing and highlighting the need for a close and sustained evaluation of virus susceptibility. This study aimed to analyze and characterize the phenotypic and genotypic NAIs susceptibility profiles of A(H1N1)pdm09 viruses circulating in Portugal from 2009 to 2010/2011. A total of 144 cases of A(H1N1)pdm09 virus infection from community and hospitalized patients were studied, including three suspected cases of clinical resistance to oseltamivir. Oseltamivir resistance was confirmed for two of the suspected cases. Neuraminidase (NA) H275Y resistant marker was found in viruses from both cases but for one it was only present in 26.2% of virus population, raising questions about the minimal percentage of resistant virus that should be considered relevant. Cross-decreased susceptibility to oseltamivir and zanamivir (2-4 IC50 fold-change) was detected on viruses from two potentially linked community patients from 2009. Both viruses harbored the NA I223V mutation. NA Y155H mutation was found in 18 statistical non-outlier viruses from 2009, having no impact on virus susceptibility. The mutations at NA N369K and V241I may have contributed to the significantly higher baseline IC50 value obtained to oseltamivir for 2010/2011 viruses, compared to viruses from the pandemic period. These results may contribute to a better understanding of the relationship between phenotype and genotype, which is currently challenging, and to the global assessment of A(H1N1)pdm09 virus susceptibility profile and baseline level to NAIs.

Evolution of the Human Immunodeficiency Virus Type 2 Envelope in the First Years of Infection is Associated with the Dynamics of the Neutralizing Antibody Response

Background: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+ T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during acute infection and their impact in HIV-2 evolution and disease progression remain largely unknown. Our objective was to characterize the Nab response and the molecular and phenotypic evolution of HIV-2 in association with Nab escape in the first years of infection in two children infected at birth. Results: CD4+ T cells decreased from about 50% to below 30% in both children in the first five years of infection and the infecting R5 viruses were replaced by X4 viruses within the same period. With antiretroviral therapy, viral load in child 1 decreased to undetectable levels and CD4+ T cells recovered to normal levels, which have been sustained at least until the age of 12. In contrast, viral load increased in child 2 and she progressed to AIDS and death at age 9. Beginning in the first year of life, child 1 raised high titers of antibodies that neutralized primary R5 isolates more effectively than X4 isolates, both autologous and heterologous. Child 2 raised a weak X4-specific Nab response that decreased sharply as disease progressed. Rate of evolution, nucleotide and amino acid diversity, and positive selection, were significantly higher in the envelope of child 1 compared to child 2. Rates of R5-to-X4 tropism switch, of V1 and V3 sequence diversification, and of convergence of V3 to a β-hairpin structure were related with rate of escape from the neutralizing antibodies. Conclusion: Our data suggests that the molecular and phenotypic evolution of the human immunodeficiency virus type 2 envelope are related with the dynamics of the neutralizing antibody response providing further support for a model in which Nabs play an important role in HIV-2 pathogenesis.